Back to top
more

HYPERION THERAPEUTICS INC (HPTX)

(Delayed Data from NSDQ)

$45.99 USD

45.99
308,104

+0.02 (0.04%)

Updated May 7, 2015 04:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[HPTX]

Reports for Purchase

Showing records 1 - 20 ( 37 total )

Industry: Medical - Drugs

Record: 1

05/27/2015

Company Report

Pages: 4

Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 2

05/07/2015

Company Report

Pages: 4

Dropping Coverage Due to Acquisition

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 3

05/05/2015

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for HPTX

Provider: ValuEngine, Inc

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 4

04/07/2015

Industry Report

Pages: 2

Healthcare -Biotechnology: Catalyst Tracker Through Mid-15

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 5

03/31/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 6

03/30/2015

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 7

03/30/2015

Company Report

Pages: 4

Downgrading to NEUTRAL; Thriving UCD Business Too Good to Resist - Horizon to Acquire Hyperion

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 8

03/30/2015

Company Report

Pages: 7

Acquisition Pending, Lowering to Neutral

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 9

03/30/2015

Industry Report

Pages: 2

Healthcare: Biotechnology: Its Yogi Berra All Over Again

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 10

03/23/2015

Company Report

Pages: 10

Worth the Wait - HE Trial Initiation on the Horizon with Design to Mitigate Risk; Increasing PT to $52

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 11

03/18/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 12

03/18/2015

Company Report

Pages: 7

Ravicti Franchise has Room to Grow, Increasing Target to $50

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 13

03/16/2015

Industry Report

Pages: 2

Healthcare - Biotechnology: Key Takeaways From the 27th Annual Conference

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 14

02/27/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 15

02/27/2015

Company Report

Pages: 8

Robust Execution Coupled With Above Consensus Guidance

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 16

02/26/2015

Company Report

Pages: 7

Back in Black with Strong 4Q; Increasing Price target to $36

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 17

02/17/2015

Industry Report

Pages: 3

Biotechnology/Biopharma: 27th Annual ROTH Conference: Healthcare Track Preview

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 18

02/12/2015

Company Report

Pages: 5

Key Takeaways from Management Meetings, Robust UCD-Franchise Growing Stronger

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 19

02/11/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 20

02/10/2015

Company Report

Pages: 5

Label Expansion Study in Infants Underway

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party
// eof